priors.science/reviews/treatment-resistant-depression

Treatment Resistant Depression

The current evidence on 6 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

6claims tracked
73primary papers reviewed
10 Aug 2026latest evidence review
Weeklyre-scored against new papers
0 Established · 5 Likely · 1 Uncertain · 0 Doubtful  |  four-reviewer panel · PICO Framework
ClaimStandingEvidence certaintyCorpus
Electroconvulsive therapy remission in treatment-resistant depressionNeurostimulationLikely84%10
Intravenous ketamine rapid responseRapid Acting GlutamatergicLong-standingLikely83%11
Esketamine adjunct in treatment-resistant depressionRapid Acting GlutamatergicLong-standingLikely79%10
Antipsychotic augmentationPharmacological AugmentationLikely74%11
Repetitive transcranial magnetic stimulation reduces treatment-resistant depression symptomsNeurostimulationLikely74%18
Psilocybin in treatment-resistant depressionNovel EmergingUncertain68%13
Track Treatment Resistant Depression.
These claims are re-scored against new papers every week. Track this topic for the full review, including each claim’s challenge and the papers behind it.
Track this topic →
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely70–84%Well supported, with some gaps or indirect evidence.
Uncertain50–69%Mixed or limited evidence. Genuinely open.
Doubtful30–49%Little support; the weight of evidence leans against it.
Refuted< 30%The evidence contradicts it — confidently false as stated.
Where the evidence sits in time
Long-standingMost of this evidence is older than the rest of this field.